Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995

Ann Surg. 1989 Jul;210(1):56-8. doi: 10.1097/00000658-198907000-00009.

Abstract

Twenty-seven patients with postoperative enterocutaneous fistulas were treated with parenteral nutrition and SMS 201-995 (100 micrograms/8 hours, subcutaneously), a long half-life somatostatin analogue. At the time SMS 201-995 was started, 11 patients had low output fistulas (less than 1000 ml/48 hours), 11 patients had high output fistulas (above 1000 ml/48 hours), and 5 patients had fistulas sitting in large abdominal wall defects. Within 24 hours of treatment, a mean reduction of 55% of the fistula output was observed. Fistula site or output before treatment had no influence on the magnitude of output reduction. Spontaneous closure was achieved in 77% of the patients after a mean of 5.8 +/- 2.7 days of treatment with this drug. Two patients died (7.4%). Pain at the injection site was referred by 15% of the patients but no other side effects were observed. Glucose intolerance was not observed. SMS 201-995 has been shown to be very useful in the conservative treatment of enterocutaneous fistulas because of its ability to rapidly reduce fistula output and accelerate spontaneous closure.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Female
  • Fistula / drug therapy*
  • Fistula / etiology
  • Fistula / therapy
  • Humans
  • Intestinal Fistula / drug therapy*
  • Intestinal Fistula / etiology
  • Intestinal Fistula / therapy
  • Male
  • Middle Aged
  • Octreotide / therapeutic use*
  • Parenteral Nutrition
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / therapy
  • Random Allocation
  • Skin Diseases / drug therapy*
  • Skin Diseases / etiology
  • Skin Diseases / therapy

Substances

  • Octreotide